PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634595
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634595
Most primary eye cancers are uveal melanoma (UM). Metastases appear in about 50% of UM patients. Metastatic UM has not been as successfully treated with systemic therapies as cutaneous melanoma, where immunotherapy has revolutionized care. With 3-5% of all melanomas, UM is the most frequent primary malignancy in adults. Although it can also develop from the iris (3%-5%) and ciliary body (5-8%), UM is most frequently found in choroidal melanocytes (85-90%). Sphere-sparing therapy or resection are the two main types of treatment for localized UM. Radiation, surgical, and laser therapies can be broadly categorized as ball-sparing treatments.
Description
The most frequent primary eye cancer is uveal melanoma (UM). Metastases appear in about 50% of UM patients. It has been harder to find effective systemic treatments for metastatic UM than for cutaneous melanoma, where immunotherapy has transformed care. Despite significant advancements in our knowledge of uveal melanoma (UM) over the past ten years, this rare tumor is still frequently misdiagnosed. Although UM, like other melanomas, arises from melanocytes, it differs significantly from cutaneous melanoma and the majority of other melanoma subtypes in terms of epidemiology, etiology, biology, and clinical characteristics. interesting. Numerous diagnostic chromosomal alterations, somatic mutations, and gene expression profiles are carried out at UM, enabling customized active surveillance plans and customized follow-up clinical trials. For disseminated UM, there is no established systemic therapy. UM does not have BRAF mutations, which restrict the use of B-Raf inhibitors, unlike cutaneous melanomas. Immune checkpoint inhibitors rarely work on these tumors despite some immune infiltration, perhaps as a result of the low mutational burden. Worldwide, UM patients deal with both uncommon cancer-related problems and UM-specific issues, which are exacerbated by the widespread misconception that skin is a subtype of cancer. skin tumors.
Uveal Melanoma (Epidemiology)
UM accounts for 3-5% of all melanomas in adults and is the most frequent primary intraocular malignancy. UM typically develops from choroidal melanocytes (85-90%), but it can also develop from the iris (3-5%) and ciliary body (5-8%) in some cases. Although the peak range for diagnosis is between 70 and 79 years old, the median age of diagnosis is roughly 62 years. By race, gender, and nation, UM incidence varies. When compared to women, males have a 30% higher incidence. The incidence is roughly five per million people in the US, with non-Hispanic whites having a significantly higher incidence than blacks and Asians (0.31 and 0.39 per million, respectively). At 1.67 per million, Hispanic incidence is average. 1,6,7 In Europe, incidence rises with latitude, averaging two cases per million in Spain and Italy, four to six cases per million in Central Europe, and more than eight cases per million in Denmark and Norway. 8 The incidence in South Korea is 0.42 per million, which is comparable to Asians in the US.
Uveal Melanoma -Current Market Size & Forecast Trends
The market for uveal melanoma is projected to grow significantly, with estimates indicating a value of approximately USD 1 billion in 2024 and expected to reach around USD 1.6 billion by 2035, reflecting a compound annual growth rate (CAGR) of 4.28% during this period. The growth is driven by increasing incidence rates, advancements in treatment options such as immune checkpoint inhibitors and proton therapy, and rising awareness of the disease.
Resection or sphere-sparing therapy are the two main forms of treatment for localized UM. Radiation therapy, surgery, and laser therapy are three broad categories of ball-sparing treatment. The COMS study, which randomly assigned patients with medium-sized choroidal melanoma to 125I brachytherapy versus resection, found that plaque brachytherapy is the most common method of treatment for primary UM lesions in the United States. Brachytherapy, photon-based external beam radiation, and charged particle radiation are all types of radiation therapy. Although long-term vision loss is common, these techniques demonstrate excellent local control and protection of the environment. Brachytherapy involves mounting a radioactive plate on the ceiling to target the tumor with a fixed dose of focused radiation. The most frequent treatment for UM is resection, which should be used in patients who have significant extraocular growth, peripheral tumor invasion, and a large tumor diameter. Translaminectomy and transretinal fusion are two alternative surgical techniques. Transpupillary hyperthermia (TTT) and photodynamic laser photocoagulation (PDLPC) are methods for delivering focused energy to destroy tumor vascular sources and lessen local recurrence by injecting and activating photosensitizing substances and free radicals. TTT may be used as adjuvant therapy following brachytherapy in cases where radiation is restricted for plaque folding because it has demonstrated some efficacy in the treatment of residual choroidal melanoma. Tebentafusp, a first-in-class bispecific fusion protein used as a CD3 T-cell driver, was given FDA approval in January 2022. Company. The only drug approved in the US to date is also this one. Food and Drug Administration as the first to demonstrate a survival benefit in patients with the disease and for the treatment of unresectable or metastatic uveal melanoma.
Report Highlights
Uveal Melanoma - Current Market Trends
Uveal Melanoma - Current & Forecasted Cases across the G8 Countries
Uveal Melanoma - Market Opportunities and Sales Potential for Agents
Uveal Melanoma - Patient-based Market Forecast to 2035
Uveal Melanoma - Untapped Business Opportunities
Uveal Melanoma - Product Positioning Vis-a-vis Competitors' Products
Uveal Melanoma - KOLs Insight